Current Report Filing (8-k)
November 27 2018 - 4:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
November 27, 2018
Date of Report (Date of earliest event reported)
|
ACURA PHARMACEUTICALS, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
|
State of New York
|
|
1-10113
|
|
11-0853640
|
(State of Other Jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
|
|
Identification Number)
|
616 N. North Court, Suite 120
Palatine, Illinois 60067
(Address of principal executive offices)
(Zip Code)
(847) 705-7709
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17CFR240.14d- 2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17CFR 240.13e- 4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 2.02
|
Results of Operations and Financial Condition
|
On November 27, 2018 we issued a press release
disclosing the financial results for our third quarter ended September 30, 2018. A copy of our press release is being furnished
as Exhibit 99.1 hereto.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
ACURA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
By:
|
/s/ Peter A. Clemens
|
|
|
|
Peter A. Clemens
|
|
|
|
Senior Vice President & Chief Financial Officer
|
|
|
|
|
Date: November 27, 2018
|
|
|
|
Exhibit Index
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From Apr 2024 to May 2024
Acura Pharmaceuticals (CE) (USOTC:ACUR)
Historical Stock Chart
From May 2023 to May 2024